- Home
- LTRN vs AKTX Comparison
LTRN vs AKTX Comparison
Compare LTRN & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- AKTX
- Stock Information
- Founded
- LTRN 2013
- AKTX N/A
- Country
- LTRN United States
- AKTX United States
- Employees
- LTRN N/A
- AKTX N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- AKTX Health Care
- Exchange
- LTRN Nasdaq
- AKTX Nasdaq
- Market Cap
- LTRN 33.7M
- AKTX 32.8M
- IPO Year
- LTRN 2020
- AKTX N/A
- Fundamental
- Price
- LTRN $4.81
- AKTX $1.19
- Analyst Decision
- LTRN Hold
- AKTX
- Analyst Count
- LTRN 1
- AKTX 0
- Target Price
- LTRN N/A
- AKTX N/A
- AVG Volume (30 Days)
- LTRN 163.3K
- AKTX 26.2K
- Earning Date
- LTRN 03-17-2025
- AKTX 02-24-2025
- Dividend Yield
- LTRN N/A
- AKTX N/A
- EPS Growth
- LTRN N/A
- AKTX N/A
- EPS
- LTRN N/A
- AKTX N/A
- Revenue
- LTRN N/A
- AKTX N/A
- Revenue This Year
- LTRN N/A
- AKTX N/A
- Revenue Next Year
- LTRN N/A
- AKTX N/A
- P/E Ratio
- LTRN N/A
- AKTX N/A
- Revenue Growth
- LTRN N/A
- AKTX N/A
- 52 Week Low
- LTRN $2.79
- AKTX $0.90
- 52 Week High
- LTRN $11.99
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- LTRN 55.42
- AKTX 43.41
- Support Level
- LTRN $4.60
- AKTX $1.10
- Resistance Level
- LTRN $5.70
- AKTX $1.33
- Average True Range (ATR)
- LTRN 0.64
- AKTX 0.15
- MACD
- LTRN -0.02
- AKTX -0.01
- Stochastic Oscillator
- LTRN 33.54
- AKTX 9.23
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).